Literature DB >> 12946731

Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial.

H Padma-Nathan1, V J Stecher, M Sweeney, J Orazem, L-J Tseng, H Deriesthal.   

Abstract

OBJECTIVES: To determine the minimal time to successful intercourse after taking sildenafil citrate for erectile dysfunction (ED).
METHODS: Male patients with ED (mean age 60 years; mean ED duration 7.0 years) who were successfully treated with sildenafil (100 mg) for 2 months or longer were randomized to sildenafil (n = 115) or placebo (n = 113) for 4 weeks of double-blind treatment. Using a stopwatch, patients recorded the time needed to obtain an erection hard enough for sexual intercourse after taking the study drug at least 2 hours after eating.
RESULTS: Within 14 and 20 minutes of sildenafil dosing, 35% and 51% of sildenafil-treated patients, respectively, versus 22% and 30% of placebo-treated patients, respectively, had an erection that led to successful intercourse (P <0.05 for both). The median time to erection leading to successful intercourse after sildenafil dosing was 36 minutes compared with 141 minutes for placebo.
CONCLUSIONS: In this study, slightly more than one half of a population of prior sildenafil responders achieved an erection that led to successful sexual intercourse within 20 minutes of sildenafil administration, suggesting that the onset of action of sildenafil can be less than 30 minutes in men with ED.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946731     DOI: 10.1016/s0090-4295(03)00567-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

1.  Optimizing outcomes of oral therapy for patients with erectile dysfunction.

Authors:  James H Barada
Journal:  Rev Urol       Date:  2003

2.  PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.

Authors:  Harin Padma-Nathan
Journal:  Rev Urol       Date:  2005

3.  Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction.

Authors:  Gregory A Broderick
Journal:  Rev Urol       Date:  2003

Review 4.  Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials.

Authors:  Mariacristina Vecchio; Sankar D Navaneethan; David W Johnson; Giuseppe Lucisano; Giusi Graziano; Marialuisa Querques; Valeria Saglimbene; Marinella Ruospo; Carmen Bonifati; Emmanuele A Jannini; Giovanni F M Strippoli
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

Review 5.  A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.

Authors:  Kyung-Hee Kim; Hyung-Kwan Kim; In-Chang Hwang; Seung-Pyo Lee; Hyun-Jai Cho; Hyun-Jae Kang; Yong-Jin Kim; Dae-Won Sohn
Journal:  Trials       Date:  2013-06-22       Impact factor: 2.279

7.  Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.

Authors:  M T Rosenberg; P L Adams; T A McBride; J N Roberts; S W McCallum
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

Review 8.  Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

Authors:  Yoram Vardi
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 9.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

Review 10.  Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies.

Authors:  Harin Padma-Nathan; Andrew McCullough; Christopher Forest
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.